Prime Medicine, Inc.

Prime Medicine, Inc. announced that the New Zealand Medicines and Medical Devices Safety Authority (Medsafe) has cleared its Clinical Trial Application (CTA) for PM577a, an investigational Prime Editor for Wilson Disease. This represents the company's first clinical authorization for an in vivo Prime Editing therapy. Prime Medicine expects to initiate a global Phase 1/2 clinical trial in the second half of 2026, with initial clinical data anticipated in 2027. PM577a targets the H1069Q mutation, the most prevalent Wilson Disease-causing allele in North America and Europe, with plans for additional products to address other pathogenic variants globally.

Prime Medicine, Inc. announced that its Chief Executive Officer, Allan Reine, M.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference. The event is scheduled for Thursday, June 4, 2026, at 12:50 p.m. ET in New York, NY. A live audio webcast and a 90-day replay will be available on the company's website.

Prime Medicine reported a net loss of $49.1 million for the first quarter of 2026, an improvement from $51.9 million in the prior year. However, the company's management has concluded that substantial doubt exists about its ability to continue as a going concern for the next 12 months, citing dependence on obtaining additional financing. As of March 31, 2026, the company held $135.5 million in cash, cash equivalents, and short-term investments, with an accumulated deficit of $937.5 million.

Prime Medicine reported a Q1 2026 net loss of $49.1 million, an improvement from $51.9 million in Q1 2025. The company announced pipeline progress, including being on track to file IND/CTA for PM577 and PM647 in H1 and mid-2026, respectively, with initial clinical data expected in 2027. Additionally, Svetlana Makhni was appointed as Chief Financial Officer in April 2026, and the company maintains a cash runway into 2027 with $149.2 million in cash and investments.

Prime Medicine, Inc. reported its first-quarter 2026 financial results and provided a business update, highlighting significant pipeline progress. The company remains on track to file IND/CTA applications for PM577 in Wilson Disease in H1 2026 and PM647 in AATD mid-2026, with initial clinical data from both programs anticipated in 2027. Prime Medicine also announced the appointment of Svetlana Makhni as Chief Financial Officer and reported a cash position of $149.2 million as of March 31, 2026, providing a cash runway into 2027.

Prime Medicine, Inc. has appointed Svetlana Makhni as its new Chief Financial Officer, effective April 16, 2026. Ms. Makhni will report to the Chief Executive Officer and will be based in Cambridge, Massachusetts. Her compensation package includes an annual base salary of $495,000 and eligibility for an annual target performance bonus of 40% of her base salary.